HIV

When left untreated, this gut condition an inflamed can accelerate arterial disease, which can lead to a heart attack or stroke, according to research from UCLA.

Study results show that these regimens increased the chances of treatment success among individuals aged 3 to 18 years compared to standard therapeutics.

The findings showed that people with HIV were 68% more likely to develop heart failure than people who did not have HIV.

Cabenuva (Cabotegravir-rilpivirine) is a 2-drug co-packaged product indicated as a complete regimen for the treatment of HIV-1 infection in adults.

Immunocompromised individuals are at a higher risk of developing severe symptoms and dying from COVID-19.

The long-acting antiretroviral therapy is intended to replace antiretroviral regimens for individuals who are virologically suppressed.

In this video, Dr. Sherman recommends strategies for solving drug therapy related problems common to long-acting antiretroviral agents, such as missed doses, adverse drug reactions and drug–drug interactions.

In this video, Dr. Sherman explains the recent data surrounding the right candidates for long-acting cabotegravir for HIV prevention.

In this video, Dr. Sherman describes the pharmacology and pharmacokinetics of cabotegravir and rilpivirine as long acting injectable antiretroviral therapy agents.

In this video, Dr. Sherman describes what pre-exposure prophylaxis is and how long-acting injectable antiretroviral agents can help to prevent HIV and may even improve adherence.

Marinol is a cannabinoid indicated for anorexia associated with weight loss in patients with AIDS.

The data included more than 21,500 children and adolescents 17 years of age and younger with HIV and more than 255,000 adults with HIV, all of whom began receiving ART between 2010 and 2019.

Ten quiz questions to assess your knowledge on common symptoms and treatments for HIV.

Juluca is indicated as a complete regimen for the treatment of HIV-1 infection in adults.

Receipt of PrEP education or prescription relies heavily on a provider’s discretion, which can be subject to social biases.

The study also collected patient-reported outcomes in routine clinical practice to understand the impact of treatment on health-related quality of life.

The success of the COVID-19 messenger RNA (mRNA) vaccines from Pfizer/BioNTech and Moderna has given many HIV advocates hope that a preventive mRNA vaccine is on the horizon.

Phase 3 ILLUMINATE showed the percentage of individuals with HIV-1 RNA levels ≥50 copies/mL for the once-a-day combination pill of doravirine/islatravir.

After switching to Biktarvy, 91% of patients remained virologically suppressed at week 24 in a cohort study.

The authors said stigmatization threatens societal cohesion during times of national upheaval, such as during a pandemic.

Medication adherence, diet, and exercise are each critical components in caring for patients with a chronic illness, but each is difficult to be managed by physicians alone.

In order to handle workflow disruptions, it is essential to train technicians and other staff to incorporate them into the patient care process and to manage paperwork and other related tasks.

PQA course provides an overview of how to build the best HIV treatment regimen and assess treatment outcomes.

This approval will provide further treatment options for younger children living with HIV, according to a ViiV press release.

Additionally, the ITT-E population showed both treatment arms showing a high proportion of participants with plasma HIV-1 RNA c/mL with dolutegravir/lamivudine demonstrating non-inferior virologic suppression to the TAF-based regimen.

The medication receives the approval after it was shown to be more effective than daily tenofovir disoproxil fumarate with emtricitabine tablets.

Because Biktarvy is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended.

Khalili and his colleagues have completed preclinical studies that have shown that EBT-101 can effectively excise HIV proviral DNA from the genomes of different cells and tissues, including HIV-infected human cells and cells and tissues of humanized mice.

The 5 largest specialty therapeutic groups—oncology, autoimmune, immunology, HIV, and multiple sclerosis—will account for 74% of specialty spending growth over the next five years.

The findings, published in the Journal of the American Heart Association, add to a list of cardiac risks experienced by patients with HIV.